Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Completed1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed133%
active_not_recruiting133%
recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_3

A Gaucher Disease Gene Therapy Trial With FLT201

NCT07223944
completedphase_1

A Gene Therapy Study in Patients With Gaucher Disease Type 1

NCT05324943
active_not_recruitingphase_1

Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

NCT06545136

Clinical Trials (3)

Showing 3 of 3 trials
NCT07223944Phase 3

A Gaucher Disease Gene Therapy Trial With FLT201

Recruiting
NCT05324943Phase 1

A Gene Therapy Study in Patients With Gaucher Disease Type 1

Completed
NCT06545136Phase 1

Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
3